Liver carcinoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
|
28284560 |
2017 |
Delirium
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
After brief cognitive testing and the Delirium Symptom Interview, delirium and delirium severity were rated daily in the hospital using the Confusion Assessment Method (CAM) and CAM-Severity score, the Delirium Rating Scale-Revised-98 (DRS-R-98), and the Memorial Delirium Assessment Scale (MDAS).
|
30032141 |
2019 |
Delirium
|
0.100 |
Biomarker
|
disease |
BEFREE |
Higher severity of delirium as indicated by the total DRS-R98 score and the total DRS-R98 severity score were associated with higher severity of PTSD symptoms.
|
31376870 |
2019 |
Delirium
|
0.100 |
Biomarker
|
disease |
BEFREE |
Primary endpoint was delirium response rate (DRR), defined as number of patients with DRS-R-98 severity score <15.25 and ≥4.5 points reduction.
|
31801901 |
2019 |
Delirium
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this prospective cohort study, 225 intensive care patients with Richmond Agitation and Sedation Scale (RASS) scores of -1 - drowsy and 0 - alert and calm were evaluated with the Delirium Rating Scale-Revised-1998 (DRS-R-98) and the Diagnostic and Statistical Manual 4th edition text revision (DSM-IV-TR)-determined diagnosis of delirium.
|
31535614 |
2019 |
Delirium
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Patients with advanced cancer admitted to the medical oncology ward were screened for delirium with the DOS and DRS-R-98.
|
30782151 |
2019 |
Delirium
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Neither median delirium/coma-free days (P = .361) nor median change in delirium severity scores (P = .582 for DRS-R-98; P = .333 for CAM-ICU-7) were different between groups.
|
30664239 |
2019 |
Delirium
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The ability of the DRS-R-98 items to discriminate between either form of delirium was substantial.
|
28262089 |
2018 |
Delirium
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Harmonization of delirium severity instruments: a comparison of the DRS-R-98, MDAS, and CAM-S using item response theory.
|
30200896 |
2018 |
Delirium
|
0.100 |
Biomarker
|
disease |
BEFREE |
Medical inpatients of ≥70 years were assessed on admission for delirium using the Revised Delirium Rating Scale (DRS-R98) and those with prevalent delirium were excluded.
|
29966197 |
2018 |
Delirium
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
DRS-R-98 items were subgrouped to represent subscores representing the three core domains of delirium (cognitive, higher-order thinking, and circadian), noncore accessory symptoms (psychotic and affective), and diagnostic characteristics (temporal onset, fluctuation, and physical disorder).
|
30045679 |
2018 |
Delirium
|
0.100 |
Biomarker
|
disease |
BEFREE |
Discharge to a care home was associated only with DRS-R98 defined delirium.
|
28903799 |
2018 |
Delirium
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Delirium severity was assessed using Delirium Rating Scale Revised-98 (DRS-R-98) and Cognitive Assessment Method severity score (CAM-sev).
|
27917740 |
2017 |
Delirium
|
0.100 |
Biomarker
|
disease |
BEFREE |
DRS-R98 profiles were essentially the same in delirium and SSD subgroups with or without dementia, although total scale scores were generally higher when in comorbid subgroups.
|
28116342 |
2017 |
Delirium
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Delirium was defined with DRS-R98 (score > 16) and recovery from delirium as ≥2 consecutive assessments without delirium prior to discharge.
|
28280733 |
2017 |
Delirium
|
0.100 |
Biomarker
|
disease |
BEFREE |
The longitudinal relationship between DRS-R98 and Richards-Campbell Sleep Quality Scale sleep scores and delirium, also with dementia as a covariate, was evaluated using generalized estimating equation logistic regression.
|
28275701 |
2017 |
Delirium
|
0.100 |
Biomarker
|
disease |
BEFREE |
The severity of delirium symptoms was assessed daily using the Delirium Rating Scale - Revised-98 (DRS-R-98).
|
28243098 |
2017 |
Common Variable Immunodeficiency
|
0.100 |
GeneticVariation
|
disease |
GWASDB |
Genome-wide association identifies diverse causes of common variable immunodeficiency.
|
21497890 |
2011 |
Delirium
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Similarly lower levels of IGF-I, and high levels of IFN-gamma, are statistically significantly (P < 0.05) associated with higher DRS scores (more severe delirium).
|
19269948 |
2009 |
Short stature
|
0.100 |
GeneticVariation
|
phenotype |
CLINVAR |
|
|
|
Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
ASB2, MEIS2, and SRPX also showed significantly lower expression in high-risk Gleason score 8 tumors as compared to low or intermediate risk tumors, suggesting that these genes may be particularly useful as indicators of PCa progression.
|
30917865 |
2019 |
Neoplasms
|
0.060 |
AlteredExpression
|
group |
BEFREE |
Moreover, downregulation of the expression of tumor-suppressor genes SRPX and FLNC further promoted apoptosis and metastasis.
|
28184944 |
2017 |
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Confocal microscopy using ([Alexa594]-(Cys0)-DRS-B2) shows that in sensitive human tumor cells (PC3), DRS-B2 seems to accumulate rapidly at the cytoplasmic membranes and enters the cytoplasm and the nucleus, while in less sensitive tumor cells (U87MG), DRS-B2 is found packed in vesicles at the cell membrane.
|
28797092 |
2017 |
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Because SRPX1, which is known as a tumor suppressor gene, reportedly induced apoptosis in tumor cells, we hypothesized that SRPX1 may play an important role in Aβ-induced apoptosis in CAA.
|
28478503 |
2017 |
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Our results indicate that down-regulation of drs mRNA is closely correlated with carcinomas which arise from adenomatous polyps in the course of the adenoma-carcinoma sequence, but that most carcinomas arising de novo are independent of the tumor suppressor function of the drs gene.
|
12716466 |
2002 |